3 results about "Ocular tension" patented technology

The invention discloses a calycosin-7-glucoside PLGA hydrogel applied to glaucoma surgery, and relates to the technical field of biological medicine, and the calycosin-7-glucoside PLGA hydrogel is prepared from the following components by weight: 1-5 parts of calycosin-7-glucoside, 20-40 parts of PLGA, 0.1-3 parts of an emulsion stabilizer, 3-8 parts of a hydrogel matrix, and 3-8 parts of a cross-linking agent. Through the construction of a dual slow-release system, the sustained release time is long, and the peak period of scar hyperplasia after operation can be covered; the semi-solid gel is attached to the sclera flap in a form, so that the adhesiveness of the surgical site is improved, and the side effects of the whole body and the secondary surgical rate can be reduced; the biocompatibility is excellent, no obvious toxicity or stimulation exists, and complications (such as low intraocular pressure and inflammation) of traditional anti-metabolic drugs can be avoided.

Provided are a two-component combination pharmaceutical composition and use thereof, which belong to the field of pharmaceuticals. The pharmaceutical composition comprises: carteolol or timolol, netarsudil, a buffer, a tonicity agent, a pH regulator, a tackifier, and water for injection. By adding the pH regulator to a solution of netarsudil free base and carteolol free base or timolol free base, the problem that netarsudil is immiscible with carteolol or timolol is successfully solved. The preparation process is simple, the intraocular pressure is reduced by means of different mechanisms of action, and the therapeutic effect is significant and precise. The ophthalmic pharmaceutical composition provides the possibility for clinically safe and effective reduction of intraocular pressure and treatment of glaucoma.

The invention relates to the technical field of glaucoma treatment equipment, in particular to a sustained-release administration glaucoma drainage stent and a preparation method thereof.The sustained-release administration glaucoma drainage stent comprises a stent body, the stent body comprises a drainage tube and a disc, the surface of the stent body is coated with an anti-scar drug coating, and the anti-scar drug coating is prepared by mixing an anti-scar drug and a degradable polymer; a plurality of micro-cavities and drainage channels are arranged on the disc, the drainage channels penetrate through the micro-cavities and are communicated with the interiors of the micro-cavities, one end of the drainage tube extends into the disc and is communicated with the drainage channels, intraocular pressure reducing slow-release compounds are arranged in the micro-cavities, and porous membranes are arranged at the ends, communicated with the drainage channels, of the micro-cavities. Through the dual structure of the surface anti-scar drug coating and the built-in intraocular pressure reduction drug storage, the anti-scar and intraocular pressure reduction synergistic treatment is achieved, the glaucoma treatment effect and safety are improved, and remarkable breakthrough is achieved in the aspects of clinical treatment effect, safety, patient compliance and the like.